Do semaglutide tablets work for weight loss?

Step 1: what the trial results actually showed

The pivotal evidence comes from OASIS 4, a phase 3 trial involving 307 adults with obesity or overweight alongside at least one weight-related condition, run over 64 weeks against a placebo. Both groups followed lifestyle guidance throughout. The headline figure (13.6% average body-weight reduction) is the intention-to-treat result: it counts everyone who started, including those who stopped early or missed doses. That makes it the honest number to lead with.

Among participants who took the tablets consistently for the full duration, average weight loss reached around 17%. That gap between the two figures is worth understanding: the tablet's strict morning routine (empty stomach, plain water, 30-minute wait before food or drink) means adherence shapes outcomes more directly than with a weekly injection. Both figures come from Novo Nordisk's announcement at the time of UK approval, and the MHRA reviewed the full data package before granting the licence.

The most common side effects in the trial were gastrointestinal: nausea, diarrhoea, and constipation affected a larger proportion of the semaglutide group than the placebo group (74.0% vs 42.2%). Most were mild to moderate and eased as participants moved through the dose escalation. That pattern is familiar to prescribers from the injectable form, and the titration schedule exists partly to let the body adjust. If you are wondering whether semaglutide tablets actually work and what the evidence behind them looks like, that question is covered in detail on a dedicated page. You can also read more about the mechanism behind oral semaglutide if the biology is what you want to explore next.

Step 2: how the dosing sequence is designed to work

The tablet does not start at its full strength. Treatment begins at 1.5mg daily, moving through 4mg and 9mg before reaching the 25mg maintenance dose, with at least a month at each level. That graduated approach is not caution for caution's sake, it is how GLP-1 medicines are structured across the board to reduce the nausea that hits hardest at the start.

The daily routine matters here more than with an injection. The tablet must be taken first thing, with a small amount of plain water (up to around 120ml), before any food, coffee, or other oral medicines, and the 30-minute gap is part of the pharmacology: the absorption enhancer that carries semaglutide across the gut lining works poorly in an acidic, fed stomach. Many people find slotting it in before the kettle goes on makes the habit stick. There is no refrigeration needed, which makes travel considerably less complicated than managing an injectable pen.

Patients who are already established on the 2.4mg weekly Wegovy injection can move across to the 25mg tablet under prescriber guidance, without restarting from the lowest dose, though any switch requires a clinical assessment first. For a fuller look at the full product profile, our Wegovy tablets overview covers licensing, storage and the practicalities side by side.

Step 3: who this is licensed for, and when a prescriber will assess

The MHRA licence covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not determine suitability, a prescriber weighs up your full medical picture, including any medicines you already take and any history that might affect safety.

Semaglutide tablets are not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. They are not licensed for under-18s. Certain conditions, including a personal or family history of medullary thyroid carcinoma or a history of pancreatitis, require careful discussion before any GLP-1 medicine is considered. The NHS semaglutide medicines page lists the full set of precautions in plain language.

Wegovy tablets are not currently available on the NHS, a NICE appraisal would need to take place first. At present this is a private-prescription route. If you are weighing up the different options available, the weight-loss treatment overview sets out what is currently licensed in the UK and how the routes compare. A note on cost context: private oral semaglutide pricing follows the same logic as the injectable form, any legitimate price should include the prescription and clinical assessment, not just the medicine. Our guide to accessing semaglutide tablets explains what to expect from a regulated service.

Step 4: putting the results in perspective

Around 13–17% body-weight loss is clinically meaningful. That is not a cosmetic figure, reductions in that range are associated in the trial literature with improvements in blood pressure, blood sugar and cholesterol. The tablets work through the same GLP-1 receptor pathway as the injectable form, slowing gastric emptying and reducing appetite signals reaching the brain. The difference is the delivery route, not the biology.

What the trial also showed is that results plateau when treatment stops. Weight-loss medicines are not a short course; they work while they are taken, alongside reduced-calorie eating and regular movement. That is not a limitation unique to this medicine, it reflects how appetite regulation works at a biological level. Our prescribers are asked about this regularly, and the honest answer is that ongoing clinical review matters as much as the first prescription. More on how oral semaglutide compares to injectable forms is covered in a dedicated page if that comparison is your main question.